---
document_datetime: 2023-09-21 17:16:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/velcade-epar-all-authorised-presentations_en.pdf
document_name: velcade-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7018958
conversion_datetime: 2025-12-28 03:16:06.906499
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical Form               | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------------------|---------------------------|-----------------------|-------------|
| EU/1/04/274/001  | VELCADE           | 3.5 mg     | Powder for solution for injection | Intravenous use           | vial (glass)          | 1 vial      |
| EU/1/04/274/002  | VELCADE           | 1.0 mg     | Powder for solution for injection | Intravenous use           | vial (glass)          | 1 vial      |